Annual Cash & Cash Equivalents
$70.99 M
-$91.71 M-56.37%
December 31, 2023
Summary
- As of February 7, 2025, SAGE annual cash & cash equivalents is $70.99 million, with the most recent change of -$91.71 million (-56.37%) on December 31, 2023.
- During the last 3 years, SAGE annual cash & cash equivalents has fallen by -$1.59 billion (-95.73%).
- SAGE annual cash & cash equivalents is now -95.73% below its all-time high of $1.66 billion, reached on December 31, 2020.
Performance
SAGE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$99.63 M
-$274.00 K-0.27%
September 30, 2024
Summary
- As of February 7, 2025, SAGE quarterly cash and cash equivalents is $99.63 million, with the most recent change of -$274.00 thousand (-0.27%) on September 30, 2024.
- Over the past year, SAGE quarterly cash and cash equivalents has dropped by -$274.00 thousand (-0.27%).
- SAGE quarterly cash and cash equivalents is now -94.00% below its all-time high of $1.66 billion, reached on December 31, 2020.
Performance
SAGE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SAGE Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -56.4% | -0.3% |
3 y3 years | -95.7% | -76.4% |
5 y5 years | -62.8% | -61.6% |
SAGE Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -75.9% | at low | -66.1% | +40.3% |
5 y | 5-year | -95.7% | at low | -94.0% | +40.3% |
alltime | all time | -95.7% | +2433.6% | -94.0% | +1135.2% |
Sage Therapeutics Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $99.63 M(-0.3%) |
Jun 2024 | - | $99.90 M(-42.1%) |
Mar 2024 | - | $172.65 M(+143.2%) |
Dec 2023 | $70.99 M(-56.4%) | $70.99 M(-52.3%) |
Sep 2023 | - | $148.71 M(+22.5%) |
Jun 2023 | - | $121.42 M(-41.2%) |
Mar 2023 | - | $206.56 M(+27.0%) |
Dec 2022 | $162.70 M(-44.7%) | $162.70 M(-18.6%) |
Sep 2022 | - | $199.83 M(-3.2%) |
Jun 2022 | - | $206.51 M(+15.6%) |
Mar 2022 | - | $178.67 M(-39.3%) |
Dec 2021 | $294.23 M(-82.3%) | $294.23 M(-30.3%) |
Sep 2021 | - | $422.17 M(-17.9%) |
Jun 2021 | - | $514.16 M(-42.8%) |
Mar 2021 | - | $899.25 M(-45.9%) |
Dec 2020 | $1.66 B(+1211.0%) | $1.66 B(+801.4%) |
Sep 2020 | - | $184.27 M(-28.6%) |
Jun 2020 | - | $258.23 M(+29.5%) |
Mar 2020 | - | $199.44 M(+57.4%) |
Dec 2019 | $126.70 M | $126.70 M(-51.1%) |
Sep 2019 | - | $259.18 M(+56.0%) |
Jun 2019 | - | $166.19 M(-51.4%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2019 | - | $342.30 M(+79.3%) |
Dec 2018 | $190.94 M(-37.6%) | $190.94 M(-24.6%) |
Sep 2018 | - | $253.12 M(-22.3%) |
Jun 2018 | - | $325.83 M(-41.6%) |
Mar 2018 | - | $557.55 M(+82.1%) |
Dec 2017 | $306.24 M(+81.7%) | $306.24 M(+127.0%) |
Sep 2017 | - | $134.92 M(+1.1%) |
Jun 2017 | - | $133.45 M(-8.3%) |
Mar 2017 | - | $145.46 M(-13.7%) |
Dec 2016 | $168.52 M(-9.8%) | $168.52 M(-47.4%) |
Sep 2016 | - | $320.08 M(+69.4%) |
Jun 2016 | - | $189.00 M(-36.9%) |
Mar 2016 | - | $299.68 M(+60.5%) |
Dec 2015 | $186.75 M(+46.2%) | $186.75 M(-8.8%) |
Sep 2015 | - | $204.88 M(-8.6%) |
Jun 2015 | - | $224.23 M(+98.2%) |
Mar 2015 | - | $113.16 M(-11.4%) |
Dec 2014 | $127.77 M(+1484.0%) | $127.77 M(-6.6%) |
Sep 2014 | - | $136.73 M(+178.3%) |
Jun 2014 | - | $49.13 M(-11.4%) |
Mar 2014 | - | $55.42 M(+587.1%) |
Dec 2013 | $8.07 M(+187.9%) | $8.07 M |
Dec 2012 | $2.80 M | - |
FAQ
- What is Sage Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sage Therapeutics?
- What is Sage Therapeutics annual cash & cash equivalents year-on-year change?
- What is Sage Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Sage Therapeutics?
- What is Sage Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Sage Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SAGE is $70.99 M
What is the all time high annual cash & cash equivalents for Sage Therapeutics?
Sage Therapeutics all-time high annual cash & cash equivalents is $1.66 B
What is Sage Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SAGE annual cash & cash equivalents has changed by -$91.71 M (-56.37%)
What is Sage Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SAGE is $99.63 M
What is the all time high quarterly cash and cash equivalents for Sage Therapeutics?
Sage Therapeutics all-time high quarterly cash and cash equivalents is $1.66 B
What is Sage Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SAGE quarterly cash and cash equivalents has changed by -$274.00 K (-0.27%)